UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along

UCB Acquires Candid Therapeutics for $2.2 Billion to Boost Immunology Pipeline

UCB is set to acquire immunology specialist Candid Therapeutics in a deal valued at up to $2.2 billion, comprising $2 billion upfront and up to $200 million in milestones. This acquisition aims to bolster UCB's immunology pipeline with Candid's T cell engagers, including its lead asset cizutamig. Cizutamig is an investigational bispecific antibody designed to target BCMA on plasma cells and CD3 on T cells, facilitating the depletion of diseased B cells for autoimmune and inflammatory indications. The transaction is expected to close by the end of the second quarter or early in the third quarter, further extending the recent M&A trend in the biopharma industry.

• UCB's acquisition of Candid Therapeutics involves a significant financial commitment of $2 billion upfront, with potential additional milestone payments reaching up to $200 million, totaling $2.2 billion. This strategic move is designed to substantially enhance UCB's existing immunology pipeline by integrating Candid's innovative T cell engager platform. The deal is anticipated to be finalized by the end of the second quarter or early in the third quarter, underscoring UCB's aggressive expansion in the autoimmune and inflammatory disease space.
• Central to the acquisition is Candid's lead asset, cizutamig, an investigational bispecific antibody. This therapy operates by simultaneously binding to BCMA on plasma cells and CD3 on T cells, a mechanism designed to induce targeted depletion of disease-causing B cells while minimizing cytokine release. Cizutamig has been studied in over 100 patients across multiple myeloma and autoimmune disorders and is currently being trialed for more than 10 autoimmune and inflammatory indications, positioning it as a potential best-in-class therapy.
• This acquisition by UCB is part of a broader trend of increased M&A activity within the biopharma industry. It follows UCB's recent acquisition of Neurona Therapeutics for up to $1.15 billion in April. Other major players like Eli Lilly have spent approximately $21 billion in 2026, while Gilead and Merck have made significant plays for Tubulis ($5 billion) and Terns Pharmaceuticals ($6.7 billion), respectively, indicating a robust and active dealmaking environment across the sector.

Addressing Unmet Needs in Autoimmune and Inflammatory Diseases

The autoimmune and inflammatory disease landscape has evolved significantly over the past three years, with researchers identifying critical gaps in current therapeutic approaches and targeting specific patient populations that remain underserved. These efforts reflect both the growing global burden of autoimmune diseases and the need for more personalized treatment strategies.

• Refractory and treatment-resistant patients requiring novel therapeutic approaches, including those with chronic spontaneous urticaria refractory to H1-antihistamines and omalizumab, and patients with severe diffuse cutaneous systemic sclerosis showing resistance to conventional treatments

• Early diagnosis and intervention needs driven by increasing demand for novel analytical tools enabling early autoimmune disease diagnosis, particularly as global age-standardized prevalence rates nearly doubled from 1990 to 2021 with projected continued growth through 2032

• Cardiovascular risk management in autoimmune patients addressing the dual challenge of achieving clinical improvement while reducing cardiovascular risk in autoimmune diseases associated with accelerated atherosclerosis

• Demographic-specific populations including young and middle-aged adults (particularly females) who bear higher disease burden, and individuals in low sociodemographic index regions projected to experience substantial mortality burden from rheumatic heart disease

• Patients with complex comorbidities such as those with osteoarthritis requiring inflammatory phenotype stratification, older adults with multiple comorbidities affecting treatment selection, and patients with contraindications to standard immunotherapies due to underlying autoimmune conditions

• Underdiagnosed rare disease populations including patients with inborn errors of immunity showing median diagnostic delays of 16 months and 17.4% mortality rates, and comprehensive registry data gaps particularly in regions like India lacking prevalence and distribution data

• Treatment heterogeneity challenges in diseases like osteoarthritis where pharmacotherapy options remain limited despite being a leading cause of disability worldwide, requiring refined dosing strategies and cost-effectiveness evaluations for emerging treatments like higher-dose methotrexate

UCB's Strategic Leap into Next-Gen Autoimmune Therapies

UCB's substantial investment in Candid Therapeutics, centered on the bispecific antibody cizutamig, signals a significant strategic pivot and a bold bet on the future of autoimmune disease treatment. This acquisition is not merely about expanding a pipeline; it represents a deeper commitment to leveraging advanced immunotherapeutic modalities, specifically T-cell engagers, in areas beyond their initial oncology successes.

Cizutamig, by targeting BCMA on plasma cells and CD3 on T cells, aims to induce profound and sustained depletion of pathogenic B cells and plasma cells. While BCMA-targeted therapies have revolutionized the treatment of multiple myeloma, their application in autoimmune and inflammatory diseases is a nascent but highly promising field. Existing evidence indicates that B-cell depletion is an effective strategy in various autoimmune conditions, and the potent, T-cell-redirecting mechanism of bispecific antibodies could offer a more comprehensive and durable response compared to conventional monoclonal antibodies. This could address critical unmet needs in patients refractory to current treatments, offering an "off-the-shelf" alternative to more complex cellular therapies.

However, this innovative approach comes with inherent considerations. Bispecific T-cell engagers are known for potential immune-related toxicities, such as cytokine release syndrome and neurotoxicity, which will require careful monitoring and management in autoimmune patient populations. The specific efficacy and long-term safety profile of a BCMA/CD3 engager in the diverse landscape of autoimmune diseases, distinct from the oncology setting, will be crucial to establish through rigorous clinical development. Furthermore, the complex engineering and manufacturing of bispecific antibodies can present challenges related to structural stability and pharmacokinetics. Despite these complexities, UCB's move underscores a broader industry trend: the strategic repurposing of validated mechanisms and the relentless pursuit of next-generation antibody therapeutics to redefine treatment paradigms across multiple therapeutic areas.